Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868277 · ClinicalTrials.gov registry record · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 830
- Enrollment target
- 20
- Study locations
NCT06868277 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 830 participants, above the 317-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (162% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06868277, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 830 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Rilvegostomig
Study Locations (20)
Maryland
- Research Site - Bethesda
- Research Site - Frederick
- Research Site - Silver Spring
- Research Site - Towson
Florida
- Research Site - Bay Pines
- Research Site - Clearwater
- Research Site - St. Petersburg
Illinois
- Research Site - Chicago
- Research Site - Decatur
Iowa
- Research Site - Des Moines
- Research Site - Waterloo
Kentucky
- Research Site - Lexington
- Research Site - Owensboro
Delaware
- Research Site - Newark
Georgia
- Research Site - Marietta
Kansas
- Research Site - Leawood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 830 participants |
| Start Date | 2025-04-10 |
| Est. Completion | 2030-12-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06868277
The ClinicalTrials.gov registry entry for NCT06868277 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 830 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 317-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (162% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06868277 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Maryland, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06868277 about?
NCT06868277 is a clinical study titled "A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer". The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
What is the current status of trial NCT06868277?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 830 participants. The study started on 2025-04-10. Estimated completion is 2030-12-02.
What conditions does trial NCT06868277 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT06868277?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Rilvegostomig (BIOLOGICAL).
Who is sponsoring clinical trial NCT06868277?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06868277 being conducted?
This trial has 20 study locations across Delaware, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.